START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients

Molecular Genetics and Metabolism

Volumn 105, Issue 2, 2012, Pages 193-197

  Utz, Jeanine R Jarnes ^a   Lorentz, Cindy Pham ^a   Markowitz, Dorothy ^a   Rudser, Kyle D ^a   Diethelm Okita, Brenda ^a   Erickson, David ^a   Whitley, Chester B ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Medication therapy management; Pharmacogenetics; Phenylketonuria; PKU; Sapropterin dihydrochloride; Tetrahydrobiopterin

Indexed keywords

ARGININE; PHENYLALANINE 4 MONOOXYGENASE; PLACEBO; SAPROPTERIN; TRYPTOPHAN;

ADULT; ALLELE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PHENYLKETONURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WILD TYPE;

ADULT; ALLELES; BIOPTERIN; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME ACTIVATION; FEMALE; GENOTYPE; HUMANS; MALE; MUTATION; PHENYLALANINE; PHENYLALANINE HYDROXYLASE; PHENYLKETONURIAS;

EID: 84856081639     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.10.014     Document Type: Article

References (26)

1. Sarafoglou K., Hoffmann G., Roth K. Pediatric Endocrinology and Inborn Errors of Metabolism 2008, New York, NY.
2. Blau N., Belanger-Quintana A., Demirkol M., Feillet F., Giovannini M., MacDonald A., Trefz F.K., van Spronsen F.J. Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria. Mol. Genet. Metab. 2009, 96:158-163.
3. Leuzzi V., Tosetti M., Montanaro D., Carducci C., Artiola C., Carducci C., Antonozzi I., Burroni M., Carnevale F., Chiarotti F., Popolizio T., Giannatempo G.M., D'Alesio V., Scarabino T. The pathogenesis of the white matter abnormalities in phenylketonuria. A multimodal 3.0Tesla MRI and magnetic resonance spectroscopy (1H MRS) study. J. Inherit. Metab. Dis. 2007, 30:209-216.
4. Waisbren S.E., Noel K., Fahrbach K., Cella C., Frame D., Dorenbaum A., Levy H. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol. Genet. Metab. 2007, 92:63-70.
5. Biomarin Biomarin Kuvan® package insert 2007.
6. Blau N., Thony B. Tetrahydrobiopterin in biomedical research. J. Inherit. Metab. Dis. 2009, 32:1-2.
7. Erlandsen H., Pey A.L., Gamez A., Perez B., Desviat L.R., Aguado C., Koch R., Surendran S., Tyring S., Matalon R., Scriver C.R., Ugarte M., Martinez A., Stevens R.C. Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:16903-16908.
8. Zurfluh M.R., Zschocke J., Lindner M., Feillet F., Chery C., Burlina A., Stevens R.C., Thony B., Blau N. Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Hum. Mutat. 2008, 29:167-175.
9. Farrugia R., Scerri C.A., Montalto S.A., Parascandolo R., Neville B.G., Felice A.E. Molecular genetics of tetrahydrobiopterin (BH4) deficiency in the Maltese population. Mol. Genet. Metab. 2007, 90:277-283.
10. Fusetti F., Erlandsen H., Flatmark T., Stevens R.C. Structure of tetrameric human phenylalanine hydroxylase and its implications for phenylketonuria. J. Biol. Chem. 1998, 273:16962-16967.
11. Bjorgo E., de Carvalho R.M., Flatmark T. A comparison of kinetic and regulatory properties of the tetrameric and dimeric forms of wild-type and Thr427->Pro mutant human phenylalanine hydroxylase: contribution of the flexible hinge region Asp425-Gln429 to the tetramerization and cooperative substrate binding. Eur. J. Biochem. 2001, 268:997-1005.
12. Burton B.K., Grange D.K., Milanowski A., Vockley G., Feillet F., Crombez E.A., Abadie V., Harding C.O., Cederbaum S., Dobbelaere D., Smith A., Dorenbaum A. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J. Inherit. Metab. Dis. 2007, 30:700-707.
13. Levy H., Burton B., Cederbaum S., Scriver C. Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment. Mol. Genet. Metab. 2007, 92:287-291.
14. Trefz F.K., Burton B.K., Longo N., Casanova M.M., Gruskin D.J., Dorenbaum A., Kakkis E.D., Crombez E.A., Grange D.K., Harmatz P., Lipson M.H., Milanowski A., Randolph L.M., Vockley J., Whitley C.B., Wolff J.A., Bebchuk J., Christ-Schmidt H., Hennermann J.B. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J. Pediatr. 2009, 154:700-707.
15. Fiege B., Blau N. Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria. J. Pediatr. 2007, 150:627-630.
16. Levy H.L., Milanowski A., Chakrapani A., Cleary M., Lee P., Trefz F.K., Whitley C.B., Feillet F., Feigenbaum A.S., Bebchuk J.D., Christ-Schmidt H., Dorenbaum A. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 2007, 370:504-510.
17. Fiege B., Bonafe L., Ballhausen D., Baumgartner M., Thony B., Meili D., Fiori L., Giovannini M., Blau N. Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: a pilot study. Mol. Genet. Metab. 2005, 86(Suppl 1):S91-S95.
18. van Spronsen F.J., van Rijn M., van Dijk T., Smit G.P., Reijngoud D.J., Berger R., Heymans H.S. Plasma phenylalanine and tyrosine responses to different nutritional conditions (fasting/postprandial) in patients with phenylketonuria: effect of sample timing. Pediatrics 1993, 92:570-573.
19. Matalon R., Koch R., Michals-Matalon K., Moseley K., Surendran S., Tyring S., Erlandsen H., Gamez A., Stevens R.C., Romstad A., Moller L.B., Guttler F. Biopterin responsive phenylalanine hydroxylase deficiency. Genet. Med. 2004, 6:27-32.
20. Guldberg P., Rey F., Zschocke J., Romano V., Francois B., Michiels L., Ullrich K., Hoffmann G.F., Burgard P., Schmidt H., Meli C., Riva E., Dianzani I., Ponzone A., Rey J., Guttler F. A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. Am. J. Hum. Genet. 1998, 63:71-79.
21. Vockley J., Rinaldo P., Bennett M.J., Matern D., Vladutiu G.D. Synergistic heterozygosity: disease resulting from multiple partial defects in one or more metabolic pathways. Mol. Genet. Metab. 2000, 71:10-18.
22. Dipple K.M., McCabe E.R. Phenotypes of patients with "simple" Mendelian disorders are complex traits: thresholds, modifiers, and systems dynamics. Am. J. Hum. Genet. 2000, 66:1729-1735.
23. Dorfman R., Sandford A., Taylor C., Huang B., Frangolias D., Wang Y., Sang R., Pereira L., Sun L., Berthiaume Y., Tsui L.C., Pare P.D., Durie P., Corey M., Zielenski J. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J. Clin. Invest. 2008, 118:1040-1049.
24. Dipple K.M., McCabe E.R. Modifier genes convert "simple" Mendelian disorders to complex traits. Mol. Genet. Metab. 2000, 71:43-50.
25. Dipple K.M., Phelan J.K., McCabe E.R. Consequences of complexity within biological networks: robustness and health, or vulnerability and disease. Mol. Genet. Metab. 2001, 74:45-50.
26. Cederbaum S. Tetrahydrobiopterin and PKU: into the future. J. Pediatr. 2011, 158:351-353.